Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)-Reference-Cited by-同舟云学术

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)

Published:2023-04-03 Issue:4 Volume:62 Page:372-380
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Josefsson Andreas¹²³,Jellvert Åsa⁴⁵⁶,Holmberg Erik⁴⁷^ORCID,Brasso Klaus⁸,Meidahl Petersen Peter⁹,Aaltomaa Sirpa¹⁰,Luukkaa Marjaana¹¹,Verhagen Paul¹²,de Wit Ronald¹³,Ahlgren Göran¹⁴,Andrén Ove¹⁵,Castellanos Enrique¹⁶,Seke Mihalj¹⁷,Widmark Anders¹⁸^ORCID,Damber Jan-Erik¹,

Affiliation:

1. Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

2. Wallenberg Center for Molecular Medicin, Umeå University, Umeå, Sweden

3. Department of Urology and Andrology, Institute of surgery and perioperative Sciences, Umeå University, Umeå, Sweden

4. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5. Region Västra Götaland, NU Hospital Group, Department of Surgery, Uddevalla, Sweden

6. Department of Oncology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

7. Regional Cancer Centre West, Gothenburg, Sweden

8. Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

9. Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

10. Department of Urology, Kuopio University Hospital, Kuopio, Finland

11. Department of Oncology, Turku University Hospital, Turku, Finland

12. Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands

13. Department of Medical Oncology, Erasmus University Medical Centre Cancer Institute, Rotterdam, the Netherlands

14. Department of Urology, Lund University, Skåne University Hospital, Sweden

15. School of Medical Sciences, Örebro University, Örebro, Sweden

16. Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

17. Centrallasarettet Växjö, Växjö, Sweden

18. Department of Radiation Sciences, Umeå University, Umeå, Sweden

Funder

Swedish Prostate Cancer Federation

County Council for West Sweden

SPCG foundation

Knut och Alice Wallenbergs Stiftelse

Publisher

Medical Journals Sweden AB

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2023.2199940

Reference35 articles.

1. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer

2. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study

3. A Randomised Comparison of ‘Casodex’^TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer

4. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

5. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics;Cancer and Metastasis Reviews;2024-03

2. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17